Drug intelligence / Profile preview

Intralipid 20%

Development stage
Approved
Lead developer
Fresenius Kabi
Modality
Small Molecules
Administration
Intravenous
01

Overview

Intralipid 20% is a sterile, non-pyrogenic fat emulsion used clinically for parenteral nutrition and experimentally as a tool to induce acute insulin resistance in physiological research. In studies conducted by the University of Minnesota, such as 'Training Effects on Muscle Fatty Acid Metabolism,' it is administered intravenously to healthy volunteers to elevate plasma free fatty acids (FFAs) to levels typically observed in metabolic disorders. This experimental model allows researchers to investigate the mechanisms of lipotoxicity, the accumulation of intramyocellular lipid metabolites (including triacylglycerol, diacylglycerol, and ceramides), and the subsequent impairment of insulin-stimulated glucose uptake. The intervention is frequently used to compare metabolic responses between sedentary and endurance-trained individuals to understand how physical activity modulates lipid-induced insulin resistance, a key precursor to type 2 diabetes mellitus.

Brand names
Intralipid
Other names
20% lipid infusionintravenous fat emulsionlipid emulsion

Beyond the preview

Go deeper on Intralipid 20%.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Intralipid 20%.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call